228 related articles for article (PubMed ID: 33295975)
1. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.
Deng W; Wang Y; Liu X; Liu J; Wang L; Yang Z; Yang M; An Y; Tang C; Sanford NN; Kim BYS; Jiang W
JAMA Netw Open; 2020 Dec; 3(12):e2028627. PubMed ID: 33295975
[TBL] [Abstract][Full Text] [Related]
2. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
3. Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States.
Sung H; Hyun N; Leach CR; Yabroff KR; Jemal A
JAMA; 2020 Dec; 324(24):2521-2535. PubMed ID: 33351041
[TBL] [Abstract][Full Text] [Related]
4. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
Suk R; Mahale P; Sonawane K; Sikora AG; Chhatwal J; Schmeler KM; Sigel K; Cantor SB; Chiao EY; Deshmukh AA
JAMA Netw Open; 2018 Sep; 1(5):e181999. PubMed ID: 30646145
[TBL] [Abstract][Full Text] [Related]
5. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
Nanda JK; Dusza SW; Navarrete-Dechent C; Liopyris K; Marghoob AA; Marchetti MA
JAMA Dermatol; 2021 Jan; 157(1):79-83. PubMed ID: 32936222
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
Ai WZ; Keegan TH; Press DJ; Yang J; Pincus LB; Kim YH; Chang ET
JAMA Dermatol; 2014 Jul; 150(7):709-15. PubMed ID: 24718769
[TBL] [Abstract][Full Text] [Related]
8. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
9. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010.
Youlden DR; Youl PH; Soyer HP; Aitken JF; Baade PD
JAMA Dermatol; 2014 May; 150(5):526-34. PubMed ID: 25093216
[TBL] [Abstract][Full Text] [Related]
10. Risk of Subsequent Primary Kidney Cancer After Another Malignancy: A Population-based Study.
Abdel-Rahman O
Clin Genitourin Cancer; 2017 Oct; 15(5):e747-e754. PubMed ID: 28314541
[TBL] [Abstract][Full Text] [Related]
11. Associations between ocular melanoma and other primary cancers: an international population-based study.
Scélo G; Boffetta P; Autier P; Hemminki K; Pukkala E; Olsen JH; Weiderpass E; Tracey E; Brewster DH; McBride ML; Kliewer EV; Tonita JM; Pompe-Kirn V; Chia KS; Jonasson JG; Martos C; Giblin M; Brennan P
Int J Cancer; 2007 Jan; 120(1):152-9. PubMed ID: 17036322
[TBL] [Abstract][Full Text] [Related]
12. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin.
Balamurugan A; Rees JR; Kosary C; Rim SH; Li J; Stewart SL
J Am Acad Dermatol; 2011 Nov; 65(5 Suppl 1):S69-77. PubMed ID: 22018070
[TBL] [Abstract][Full Text] [Related]
13. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
14. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study.
Chakraborty S; Hauke RJ; Bonthu N; Tarantolo SR
Anticancer Res; 2012 Oct; 32(10):4507-15. PubMed ID: 23060579
[TBL] [Abstract][Full Text] [Related]
15. Excessive risk of second primary cancers in young-onset colorectal cancer survivors.
He X; Wu W; Ding Y; Li Y; Si J; Sun L
Cancer Med; 2018 Apr; 7(4):1201-1210. PubMed ID: 29533011
[TBL] [Abstract][Full Text] [Related]
16. Risk of Multiple Primary Cancers in Patients With Merkel Cell Carcinoma: A SEER-Based Analysis.
Eid E; Maloney NJ; Cai ZR; Zaba LC; Kibbi N; John EM; Linos E
JAMA Dermatol; 2023 Nov; 159(11):1248-1252. PubMed ID: 37703005
[TBL] [Abstract][Full Text] [Related]
17. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
18. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries.
Zhu G; Chen Y; Zhu Z; Lu L; Bi X; Deng Q; Chen X; Su H; Liu Y; Guo H; Zheng T; Yu H; Zhang Y
Dis Esophagus; 2012 Aug; 25(6):505-11. PubMed ID: 22067063
[TBL] [Abstract][Full Text] [Related]
19. The relative risk of second primary cancers in Austria's western states: a retrospective cohort study.
Preyer O; Concin N; Obermair A; Concin H; Ulmer H; Oberaigner W
BMC Cancer; 2017 Oct; 17(1):699. PubMed ID: 29065867
[TBL] [Abstract][Full Text] [Related]
20. Risk of second primary cancers among patients with a first primary gastric cancer: A population-based study in North Portugal.
Morais S; Antunes L; Bento MJ; Lunet N
Cancer Epidemiol; 2017 Oct; 50(Pt A):85-91. PubMed ID: 28843176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
